ArticleThe Journal of clinical endocrinology and metabolism2026
The landscape of pediatric differentiated thyroid carcinoma and predictors of invasive disease: a CATC study.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
contextDifferentiated thyroid carcinoma (DTC) is rare in children, comprising 2% to 4% of pediatric cancers. Because of low case volumes at individual institutions, comprehensive data on patient and tumor characteristics and treatment outcomes are limited. The Child and Adolescent Thyroid Consortium was established in 2019 to address this gap and to assess impact of changes in practice on outcomes.
objectiveThis inaugural Child and Adolescent Thyroid Consortium study analyzes the landscape of pediatric DTC and predictors of invasive disease.
designInternational, multicenter retrospective analysis of children (<age 19 years) with DTC diagnosed from 2010 to 2019.
settingFive high-volume pediatric centers.
resultsThe cohort included 715 children (78.3% female) diagnosed with DTC at median age 15.2 years (range: 3.2-18.9). There were 673 (94%) patients with papillary thyroid carcinoma (PTC) and 42 (6%) had follicular thyroid carcinoma. Among patients with PTC, stage 1(M0) disease was present in 562 individuals (83.5%; 222 N0, 161 N1a, and 179 N1b). Stage 2 (M1) disease was present in 111 (16.5%) children with PTC and 1/42 (2.4%) with follicular thyroid carcinoma. Males and children aged <10 years exhibited more advanced T, N, and M stages. Any extrathyroidal extension correlated with increased nodal and pulmonary metastases. Oncogenic fusions, compared with BRAFV600E, were associated with more advanced N and M stages. Deintensification of therapy since 2015 was not associated with changes in disease outcomes.
conclusionInvasive DTC is associated with age <10 years, male sex, tumors driven by oncogenic fusions, and extrathyroidal extension. Despite less aggressive therapies in recent years, disease outcomes have not worsened. Recognition of these associations may guide care and prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.